Thyroid cancers are the most common tumor associated with clonal hematopoiesis (CH), and CH is associated with worse outcomes in other solid tumor patients, although the specific consequences of CH on therapy response are unknown. Dr. Tiedje has developed a mouse model of concurrent CH and thyroid cancer to study the impact of CH on thyroid tumor biology and therapy response.
The Role of Tet2-Mutant Clonal Hematopoiesis in BRAF-V600E-Driven Anaplastic Thyroid Cancer
2024 Momentum Fellow
Vera Tiedje, MD, PhD, Memorial Sloan Kettering Cancer Center
Vera Tiedje, MD, PhD